89848-21-5

Basic information

• Product Name: Norgestrienone
• Synonyms: 2,4-Dihydro-4-[4-[4-(4-hydroxylphenyl)piperazin-1-yl]phenyl]-2-(1-methylpropyl)-3H-1,2,4-triazol-3-one;2-SEC-BUTYL-4-[4-[4-(4-HYDROXYPHENYL)PIPERAZIN-1-YL]PHENYL]-2,4-DIHYDRO-[1,2,4]TRIAZOL-3-ONE;2,4-DIHYDRO-4-[4-[4-(4-HYDROXYPHENYL)-1-PIPERAZINYL]PHENYL]-2-(1-METHYLPROPYL)-3H-1,2,4-TRIAZOLE-3-ONE;2,4-DIHYDRO-4-[(4-(4-HYDROXYPHENYL)-1-PIPERAZINYL)PHENYL]-2-(1-METHYLPROPYL)-3H-1,2,4-TRIAZOLE-3-ONE;2,4-DIHYDRO-4-[4-(4-HYDROXYPHENYL)1-PIPERAZINYLPHENYL]-2-(1-METHYL-PROPYL)-3H-1,2,4-TRIAZOL-3-ONE;2,4-DIHYDRO-4-[4-[4-(4-HYDROXYPHENYL)-1-PIPERAZINYL]-PHENYL]-2-(1-METHYLPROPYL)-3H-1,2,4-TRIAZOL-3-ONE;1-SEC BUTYL-[4[4(4-HYDROXYPHENYL)-1-PIPERAZINYL]-PHENYL]-1,2,4-TRIAZOLO-5-ONE;2,4-Dihydro-4-[[4-Hydroxyphenyl]-1-Piperazinyl]-Phenyl]-2-(1-Methylpropyl)-3H-1,
• CAS NO: 89848-21-5
• Molecular Formula: C₂₂H₂₇N₅O₂
• Molecular Weight: 393.48
• EINECS: 212-698-6
• Product Categories: INTERMEDIATESOFITRACONAZOLE
• Mol File: 89848-21-5.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 587.9 °C at 760 mmHg
• Flash Point: 309.4 °C
• Appearance: /
• Density: 1.25
• Refractive Index: 1.647
• PKA: 12.18±0.30(Predicted)
• CAS DataBase Reference: Norgestrienone(CAS DataBase Reference)
• NIST Chemistry Reference: Norgestrienone(89848-21-5)
• EPA Substance Registry System: Norgestrienone(89848-21-5)

Safety Data

• Hazardous Substances Data: 89848-21-5(Hazardous Substances Data)

Usage

General Description

Norgestrienone is a synthetic progestin medication that is used in combination with estrogen as a form of hormonal birth control. It works by preventing ovulation and changing the cervical mucus and endometrium to make it difficult for sperm to reach the uterus and for a fertilized egg to implant. Norgestrienone is also used to treat endometriosis, abnormal menstrual cycles, and menopausal symptoms. It is available in several different forms, including oral tablets, injections, and implants. Common side effects may include headaches, breast tenderness, weight gain, and changes in menstrual bleeding patterns. Like other hormonal contraceptives, norgestrienone may also carry a risk of more serious side effects, such as blood clots and an increased risk of certain types of cancer. Therefore, it should be used with caution and under the guidance of a healthcare professional.

InChI:InChI=1/C22H27N5O2/c1-3-17(2)27-22(29)26(16-23-27)21-7-5-4-6-20(21)25-14-12-24(13-15-25)18-8-10-19(28)11-9-18/h4-11,16-17,28H,3,12-15H2,1-2H3

Upstream product

• 89848-16-8 1-isobutyl-4-(4-(4-(4-methoxyphenyl)piperazin-1-yl)phenyl)-1H-1,2,4-triazol-5(4H)-one 
• 38212-30-5 4-(4-methoxyphenyl)piperazine 
• 74853-06-8 phenyl (4-(4-(4-methoxyphenyl)piperazin-1-yl)phenyl)carbamate 
• 74852-89-4 N-{4-[4-(4-methoxyphenyl)-1-piperazinyl]phenyl}hydrazinecarboxamide 
• 74853-07-9 2,4-dihydro-4-[4-[4-(4-methoxyphenyl)-1-piperazinyl ]-phenyl]-3H-1,2,4-triazol-3-one 
• 74852-61-2 1-(4-methoxyphenyl)-4-(4-nitrophenyl)-piperazine 
• 74852-62-3 4-[4-(4-methoxy-phenyl)-piperazin-1-yl]-phenylamine 
• 100-00-5 4-chlorobenzonitrile 

Downstream Products

• 1339803-67-6 cis-(2S,4R)-4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-2-isobutyl-3H-1,2,4-triazol-3-one 
• 89848-53-3 4-[4-(4-{4-[(2R,4S)-2-(2,4-Dichloro-phenyl)-2-[1,2,4]triazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-phenyl]-2-isobutyl-2,4-dihydro-[1,2,4]triazol-3-one 

Relevant articles and documents

ITRACONAZOLE ANALOGS AND USE THEREOF

Provided herein are Itraconazole analogs. Also provided herein are methods of inhibition of Hedgehog pathway, vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, angiogenesis and treatment of disease with Itraconazole analogs.

Antimycotic azoles. 7. Synthesis and antifungal properties of a series of novel triazol-3-ones

A series of novel triazol-3-ones has been synthesized, and their in vitro and in vivo antifungal properties are reported. Traconazole. which displays a pronounced oral activity against vaginal candidosis in rats and against microsporosis in guinea pigs, has been selected for clinical evaluation.